OGN
Organon & Co.
Drug Manufacturers - General
Market Cap$3.47B
5Y Perf.-62.7%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
OGN vs TEVA
Revenue, margins, valuation, and 5-year total return — side by side.
TEVA
Teva Pharmaceutical Industries Limited
Drug Manufacturers - Specialty & Generic
Market Cap$41.60B
5Y Perf.+243.6%
OGN vs TEVA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | OGN | TEVA |
|---|---|---|
| Industry | Drug Manufacturers - General | Drug Manufacturers - Specialty & Generic |
| Market Cap | $3.47B | $41.60B |
| Revenue (TTM) | $6.22B | $17.35B |
| Net Income (TTM) | $187M | $1.56B |
| Gross Margin | 53.6% | 52.1% |
| Operating Margin | 20.0% | 13.2% |
| Forward P/E | 3.9x | 15.5x |
| Total Debt | $0.00 | $17.38B |
| Cash & Equiv. | — | $3.56B |
OGN vs TEVA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
OGN
TEVA
| Stock | May 21 | May 26 | Return |
|---|---|---|---|
| Organon & Co. (OGN) | 100 | 37.3 | -62.7% |
| Teva Pharmaceutical… (TEVA) | 100 | 343.6 | +243.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: OGN vs TEVA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TEVA leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Organon & Co. is the stronger pick specifically for valuation and capital efficiency and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
OGN
Organon & Co.
The Value Play
OGN is the clearest fit if your priority is value and efficiency.
- Lower P/E (3.9x vs 15.5x)
- 20.6% ROE vs TEVA's 3.9%, ROIC 19.8% vs 7.7%
Best for: value and efficiency
TEVA
Teva Pharmaceutical Industries Limited
The Income Pick
TEVA carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 1.08
- Rev growth 4.3%, EPS growth 182.8%, 3Y rev CAGR 5.0%
- -28.8% 10Y total return vs OGN's -47.0%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | TEVA | 4.3% revenue growth vs OGN's -2.9% |
| Value | OGN | Lower P/E (3.9x vs 15.5x) |
| Quality / Margins | TEVA | 9.0% margin vs OGN's 3.0% |
| Stability / Safety | TEVA | Beta 1.08 vs OGN's 1.09 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | TEVA | +97.7% vs OGN's +48.9% |
| Efficiency (ROA) | OGN | 20.6% ROE vs TEVA's 3.9%, ROIC 19.8% vs 7.7% |
OGN vs TEVA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
OGN vs TEVA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTEVALAGGINGOGN
OGNOrganon & Co.
1leads
TEVATeva Pharmaceutical I…
3leads
6 Total Categories
CATEGORYLEADERvs OGNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
TEVA4/6
Valuation MetricsMultiples, price ratios, and targets
OGN5/5
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
TEVA5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
TEVA1/1
Income & Cash Flow (Last 12 Months)
TEVA leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TEVA is the larger business by revenue, generating $17.3B annually — 2.8x OGN's $6.2B. TEVA is the more profitable business, keeping 9.0% of every revenue dollar as net income compared to OGN's 3.0%. On growth, TEVA holds the edge at +2.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | OGNOrganon & Co. | TEVATeva Pharmaceutic… |
|---|---|---|
| RevenueTrailing 12 months | $6.2B | $17.3B |
| EBITDAEarnings before interest/tax | $1.6B | $3.3B |
| Net IncomeAfter-tax profit | $187M | $1.6B |
| Free Cash FlowCash after capex | $308M | $1.2B |
| Gross MarginGross profit ÷ Revenue | +53.6% | +52.1% |
| Operating MarginEBIT ÷ Revenue | +20.0% | +13.2% |
| Net MarginNet income ÷ Revenue | +3.0% | +9.0% |
| FCF MarginFCF ÷ Revenue | +5.0% | +6.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -5.3% | +2.3% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.9% | +72.2% |
TEVA leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
OGN leads this category, winning 5 of 5 comparable metrics.
Valuation Metrics
At 18.5x trailing earnings, OGN trades at a 38% valuation discount to TEVA's 29.8x P/E. On an enterprise value basis, OGN's 2.1x EV/EBITDA is more attractive than TEVA's 17.5x.
| Metric | OGNOrganon & Co. | TEVATeva Pharmaceutic… |
|---|---|---|
| Market CapShares × price | $3.5B | $41.6B |
| Enterprise ValueMkt cap + debt − cash | $3.5B | $55.4B |
| Trailing P/EPrice ÷ TTM EPS | 18.54x | 29.77x |
| Forward P/EPrice ÷ next-FY EPS est. | 3.88x | 15.50x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 2.12x | 17.55x |
| Price / SalesMarket cap ÷ Revenue | 0.56x | 2.41x |
| Price / BookPrice ÷ Book value/share | 3.84x | 5.30x |
| Price / FCFMarket cap ÷ FCF | — | 36.24x |
OGN leads this category, winning 5 of 5 comparable metrics.
Profitability & Efficiency
Evenly matched — OGN and TEVA each lead in 3 of 6 comparable metrics.
Profitability & Efficiency
TEVA delivers a 20.7% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $21 for OGN. On the Piotroski fundamental quality scale (0–9), TEVA scores 8/9 vs OGN's 0/9, reflecting strong financial health.
| Metric | OGNOrganon & Co. | TEVATeva Pharmaceutic… |
|---|---|---|
| ROE (TTM)Return on equity | +20.6% | +20.7% |
| ROA (TTM)Return on assets | — | +3.9% |
| ROICReturn on invested capital | +19.8% | +7.7% |
| ROCEReturn on capital employed | — | +8.0% |
| Piotroski ScoreFundamental quality 0–9 | 0 | 8 |
| Debt / EquityFinancial leverage | — | 2.20x |
| Net DebtTotal debt minus cash | $0 | $13.8B |
| Cash & Equiv.Liquid assets | — | $3.6B |
| Total DebtShort + long-term debt | $0 | $17.4B |
| Interest CoverageEBIT ÷ Interest expense | 2.36x | 2.51x |
Evenly matched — OGN and TEVA each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
TEVA leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TEVA five years ago would be worth $34,859 today (with dividends reinvested), compared to $5,302 for OGN. Over the past 12 months, TEVA leads with a +97.7% total return vs OGN's +48.9%. The 3-year compound annual growth rate (CAGR) favors TEVA at 58.0% vs OGN's -10.4% — a key indicator of consistent wealth creation.
| Metric | OGNOrganon & Co. | TEVATeva Pharmaceutic… |
|---|---|---|
| YTD ReturnYear-to-date | +84.7% | +15.4% |
| 1-Year ReturnPast 12 months | +48.9% | +97.7% |
| 3-Year ReturnCumulative with dividends | -28.2% | +294.4% |
| 5-Year ReturnCumulative with dividends | -47.0% | +248.6% |
| 10-Year ReturnCumulative with dividends | -47.0% | -28.8% |
| CAGR (3Y)Annualised 3-year return | -10.4% | +58.0% |
TEVA leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — OGN and TEVA each lead in 1 of 2 comparable metrics.
Risk & Volatility
TEVA is the less volatile stock with a 1.08 beta — it tends to amplify market swings less than OGN's 1.09 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. OGN currently trades 99.3% from its 52-week high vs TEVA's 95.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | OGNOrganon & Co. | TEVATeva Pharmaceutic… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.09x | 1.08x |
| 52-Week HighHighest price in past year | $13.44 | $37.35 |
| 52-Week LowLowest price in past year | $5.69 | $14.99 |
| % of 52W HighCurrent price vs 52-week peak | +99.3% | +95.7% |
| RSI (14)Momentum oscillator 0–100 | 77.7 | 70.6 |
| Avg Volume (50D)Average daily shares traded | 9.6M | 6.6M |
Evenly matched — OGN and TEVA each lead in 1 of 2 comparable metrics.
Analyst Outlook
TEVA leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates OGN as "Hold" and TEVA as "Buy". Consensus price targets imply 10.0% upside for TEVA (target: $39) vs -15.1% for OGN (target: $11).
| Metric | OGNOrganon & Co. | TEVATeva Pharmaceutic… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $11.33 | $39.29 |
| # AnalystsCovering analysts | 9 | 46 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
TEVA leads this category, winning 1 of 1 comparable metric.
Key Takeaway
TEVA leads in 3 of 6 categories (Income & Cash Flow, Total Returns). OGN leads in 1 (Valuation Metrics). 2 tied.
Best OverallTeva Pharmaceutical Industr… (TEVA)Leads 3 of 6 categories
Loading custom metrics...
OGN vs TEVA: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is OGN or TEVA a better buy right now?
For growth investors, Teva Pharmaceutical Industries Limited (TEVA) is the stronger pick with 4.
3% revenue growth year-over-year, versus -2. 9% for Organon & Co. (OGN). Organon & Co. (OGN) offers the better valuation at 18. 5x trailing P/E (3. 9x forward), making it the more compelling value choice. Analysts rate Teva Pharmaceutical Industries Limited (TEVA) a "Buy" — based on 46 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — OGN or TEVA?
On trailing P/E, Organon & Co.
(OGN) is the cheapest at 18. 5x versus Teva Pharmaceutical Industries Limited at 29. 8x. On forward P/E, Organon & Co. is actually cheaper at 3. 9x.
03Which is the better long-term investment — OGN or TEVA?
Over the past 5 years, Teva Pharmaceutical Industries Limited (TEVA) delivered a total return of +248.
6%, compared to -47. 0% for Organon & Co. (OGN). Over 10 years, the gap is even starker: TEVA returned -28. 8% versus OGN's -47. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — OGN or TEVA?
By beta (market sensitivity over 5 years), Teva Pharmaceutical Industries Limited (TEVA) is the lower-risk stock at 1.
08β versus Organon & Co. 's 1. 09β — meaning OGN is approximately 1% more volatile than TEVA relative to the S&P 500.
05Which is growing faster — OGN or TEVA?
By revenue growth (latest reported year), Teva Pharmaceutical Industries Limited (TEVA) is pulling ahead at 4.
3% versus -2. 9% for Organon & Co. (OGN). On earnings-per-share growth, the picture is similar: Teva Pharmaceutical Industries Limited grew EPS 182. 8% year-over-year, compared to -78. 4% for Organon & Co.. Over a 3-year CAGR, TEVA leads at 5. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — OGN or TEVA?
Teva Pharmaceutical Industries Limited (TEVA) is the more profitable company, earning 8.
2% net margin versus 3. 0% for Organon & Co. — meaning it keeps 8. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OGN leads at 20. 7% versus 12. 5% for TEVA. At the gross margin level — before operating expenses — OGN leads at 54. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is OGN or TEVA more undervalued right now?
On forward earnings alone, Organon & Co.
(OGN) trades at 3. 9x forward P/E versus 15. 5x for Teva Pharmaceutical Industries Limited — 11. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TEVA: 10. 0% to $39. 29.
08Which pays a better dividend — OGN or TEVA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is OGN or TEVA better for a retirement portfolio?
For long-horizon retirement investors, Teva Pharmaceutical Industries Limited (TEVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
08)). Both have compounded well over 10 years (TEVA: -28. 8%, OGN: -47. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between OGN and TEVA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(OGN: -5.3% · TEVA: 2.3%)Net Margin>
%
(OGN: 3.0% · TEVA: 9.0%)P/E Ratio<
x
(OGN: 18.5x · TEVA: 29.8x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.